Expanding the Horizons of Peptide Therapeutics: Mathematical Elegance and Structural Dynamics in Rational Design: A comment on "Intentional Fibonacci-Lucas-guided peptide design as a prospective experimental factor: A falsifiable, patient-centred framework for GLP-1, GIP and related therapeutics within the Geier equilibrium programme (A first approach)" by Stefan Geier et al., August 2026, DOI: 10.13140/RG.2.2.28941.91363
Expanding the Horizons of Peptide Therapeutics: Mathematical Elegance and Structural Dynamics in Rational Design: A comment on "Intentional Fibonacci-Lucas-guided peptide design as a prospective experimental factor: A falsifiable, patient-centred framework for GLP-1, GIP and related therapeutics within the Geier equilibrium programme (A first approach)" by Stefan Geier et al., August 2026, DOI: 10.13140/RG.2.2.28941.91363 The rational design of peptide therapeutics has undergone a profound evolution over the past two decades. Historically constrained by poor metabolic stability, rapid clearance, and limited oral bioavailability, peptide engineering has transitioned into an era defined by precise multi-target engagement, tailored pharmacokinetics, and sophisticated structural optimization (Day et al., 2009; Drucker, 2020; Lau et al., 2015). In their insightful review, Intentional Fibonacci-Lucas-guided peptide design as a prospective experimental factor... , Stefan A. Geier ...